<p>Truist Financial 在周二发布的研究报告中开始覆盖 Dianthus Therapeutics（NASDAQ:DNTH - 获取免费报告）的股票，Briefing.com 自动导入报道。该券商对该股票设定了 “买入” 评级和 56.00 美元的目标价。Truist Financial 的目标价表明该公司当前价格有 62.70% 的潜在上涨空间。</p>
<p>获取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
<p>其他股票分析师也对该公司发布了研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Dianthus Therapeutics 股票的 “卖出（d-）” 评级。Guggenheim 将 Dianthus Therapeutics 的目标价从 92.00 美元上调至 100.00 美元，并在 9 月 9 日的研究报告中给予该股票 “买入” 评级。Stifel Nicolaus 将 Dianthus Therapeutics 的目标价从 52.00 美元上调至 65.00 美元，并在 9 月 12 日的研究报告中给予该股票 “买入” 评级。William Blair 在 7 月 2 日的研究报告中开始覆盖 Dianthus Therapeutics，并对该公司给予了 “跑赢大盘” 的评级。最后，HC Wainwright 在 9 月 8 日的研究报告中重申了 “买入” 评级，并对 Dianthus Therapeutics 股票设定了 40.00 美元的目标价。十位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 60.88 美元。</p>
<p><strong>查看我们关于 Dianthus Therapeutics 的最新研究报告</strong></p>
<h2>Dianthus Therapeutics 股票表现</h2>
<p>NASDAQ:DNTH 周二开盘价为 34.42 美元。该股票的 50 日简单移动平均线为 29.81 美元，200 日简单移动平均线为 22.83 美元。Dianthus Therapeutics 的 52 周低点为 13.36 美元，52 周高点为 40.16 美元。该公司的市值为 11.1 亿美元，市盈率为-10.59，贝塔值为 1.58。</p>
<p>Dianthus Therapeutics（NASDAQ:DNTH - 获取免费报告）最近于 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为-0.88 美元，低于市场共识预期的-0.86 美元，差距为-0.02 美元。该公司本季度的收入为 19 万美元，而市场共识预期为 87 万美元。Dianthus Therapeutics 的净利润率为-2364.56%，股本回报率为-34.72%。股票分析师预测 Dianthus Therapeutics 本财年的每股收益将为-2.61 美元。</p>
<h2>内部活动</h2>
<p>在其他消息中，首席财务官 Ryan Savitz 于 9 月 9 日出售了 20,000 股该公司的股票。该股票以 35.00 美元的平均价格出售，总价值为 700,000.00 美元。该交易已在提交给证券交易委员会的文件中披露，您可以通过此超链接访问。16.56% 的股票由内部人士持有。</p>
<h2>机构投资者对 Dianthus Therapeutics 的看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对该公司的持股。ADAR1 Capital Management LLC 在第一季度将其在 Dianthus Therapeutics 的持股增加了 3.4%。ADAR1 Capital Management LLC 目前拥有 18,285 股该公司的股票，价值 332,000 美元，此前在该期间内又购买了 602 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Dianthus Therapeutics 的持股增加了 4.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 15,334 股该公司的股票，价值 280,000 美元，此前在该期间内又购买了 618 股。纽约梅隆银行在第一季度将其在 Dianthus Therapeutics 的持股增加了 1.0%。纽约梅隆银行目前拥有 73,638 股该公司的股票，价值 1,336,000 美元，此前在该期间内又购买了 748 股。Charles Schwab Investment Management Inc. 在第一季度将其在 Dianthus Therapeutics 的持股增加了 0.6%。Charles Schwab Investment Management Inc. 目前拥有 168,102 股该公司的股票，价值 3,049,000 美元，此前在该期间内又购买了 1,081 股。最后，Raymond James Financial Inc. 在第二季度购买了 Dianthus Therapeutics 的新股份，价值约 27,000 美元。目前 47.53% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Dianthus Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Dianthus Therapeutics, Inc. 是一家临床阶段的生物技术公司，开发针对严重自身免疫和炎症疾病的补体治疗。该公司正在开发 DNTH103，这是一种单克隆抗体，目前处于第二阶段临床试验中，旨在治疗广泛性重症肌无力、多发性运动神经病和慢性炎症脱髓鞘多神经病。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Dianthus Therapeutics</li>
<li>商业服务股票投资</li>
<li>Fastenal 股票在十月回调——现在是购买 FAST 的时机吗？</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>为什么国会在财报前购买 Intuitive Surgical</li>
<li>三只超市股票证明它们仍然是必需品</li>
<li>FICO 的大幅下跌可能是今年最佳购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Dianthus Therapeutics 吗？</h2>
<p>在考虑 Dianthus Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 Dianthus Therapeutics 并不在名单上。</p>
<p>虽然 Dianthus Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DNTH

<p>Truist Financial 已经开始覆盖 Dianthus Therapeutics (NASDAQ:DNTH)，给予 “买入” 评级，并设定目标价为 56.00 美元，表示潜在上涨空间为 62.70%。其他分析师的意见各不相同，Weiss Ratings 给出了 “卖出” 评级，而 Guggenheim 和 Stifel Nicolaus 分别设定了更高的目标价 100.00 美元和 65.00 美元。该股票目前交易价格为 34.42 美元，平均评级为 “适度买入”，目标价为 60.88 美元。Dianthus 是一家专注于自身免疫疾病治疗的临床阶段生物技术公司</p>

<p>Truist Financial began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a research note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a &#34;buy&#34; rating and a $56.00 price target on the stock. Truist Financial's target price indicates a potential upside of 62.70% from the company's current price.</p>
<div class="lb-trans"><p>Truist Financial 在周二发布的研究报告中开始覆盖 Dianthus Therapeutics（NASDAQ:DNTH - 获取免费报告）的股票，Briefing.com 自动导入报道。该券商对该股票设定了 “买入” 评级和 56.00 美元的目标价。Truist Financial 的目标价表明该公司当前价格有 62.70% 的潜在上涨空间。</p>
</div><p>Get <strong>Dianthus Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dianthus Therapeutics</strong> 的提醒：</p>
</div><p>Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Guggenheim upped their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, September 9th. Stifel Nicolaus upped their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, September 12th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an &#34;outperform&#34; rating for the company. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, September 8th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $60.88.</p>
<div class="lb-trans"><p>其他股票分析师也对该公司发布了研究报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Dianthus Therapeutics 股票的 “卖出（d-）” 评级。Guggenheim 将 Dianthus Therapeutics 的目标价从 92.00 美元上调至 100.00 美元，并在 9 月 9 日的研究报告中给予该股票 “买入” 评级。Stifel Nicolaus 将 Dianthus Therapeutics 的目标价从 52.00 美元上调至 65.00 美元，并在 9 月 12 日的研究报告中给予该股票 “买入” 评级。William Blair 在 7 月 2 日的研究报告中开始覆盖 Dianthus Therapeutics，并对该公司给予了 “跑赢大盘” 的评级。最后，HC Wainwright 在 9 月 8 日的研究报告中重申了 “买入” 评级，并对 Dianthus Therapeutics 股票设定了 40.00 美元的目标价。十位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 60.88 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Dianthus Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Dianthus Therapeutics 的最新研究报告</strong></p>
</div><h2>Dianthus Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Dianthus Therapeutics 股票表现</h2>
</div><p>NASDAQ:DNTH opened at $34.42 on Tuesday. The stock has a 50-day simple moving average of $29.81 and a two-hundred day simple moving average of $22.83. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $40.16. The firm has a market capitalization of $1.11 billion, a PE ratio of -10.59 and a beta of 1.58.</p>
<div class="lb-trans"><p>NASDAQ:DNTH 周二开盘价为 34.42 美元。该股票的 50 日简单移动平均线为 29.81 美元，200 日简单移动平均线为 22.83 美元。Dianthus Therapeutics 的 52 周低点为 13.36 美元，52 周高点为 40.16 美元。该公司的市值为 11.1 亿美元，市盈率为-10.59，贝塔值为 1.58。</p>
</div><p>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Equities analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Dianthus Therapeutics（NASDAQ:DNTH - 获取免费报告）最近于 8 月 7 日发布了季度财报。该公司报告每股收益（EPS）为-0.88 美元，低于市场共识预期的-0.86 美元，差距为-0.02 美元。该公司本季度的收入为 19 万美元，而市场共识预期为 87 万美元。Dianthus Therapeutics 的净利润率为-2364.56%，股本回报率为-34.72%。股票分析师预测 Dianthus Therapeutics 本财年的每股收益将为-2.61 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CFO Ryan Savitz sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total value of $700,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 16.56% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席财务官 Ryan Savitz 于 9 月 9 日出售了 20,000 股该公司的股票。该股票以 35.00 美元的平均价格出售，总价值为 700,000.00 美元。该交易已在提交给证券交易委员会的文件中披露，您可以通过此超链接访问。16.56% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Dianthus Therapeutics 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC raised its holdings in shares of Dianthus Therapeutics by 3.4% in the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after buying an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after buying an additional 618 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Dianthus Therapeutics by 1.0% in the first quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after buying an additional 748 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Dianthus Therapeutics by 0.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company's stock worth $3,049,000 after buying an additional 1,081 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对该公司的持股。ADAR1 Capital Management LLC 在第一季度将其在 Dianthus Therapeutics 的持股增加了 3.4%。ADAR1 Capital Management LLC 目前拥有 18,285 股该公司的股票，价值 332,000 美元，此前在该期间内又购买了 602 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Dianthus Therapeutics 的持股增加了 4.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 15,334 股该公司的股票，价值 280,000 美元，此前在该期间内又购买了 618 股。纽约梅隆银行在第一季度将其在 Dianthus Therapeutics 的持股增加了 1.0%。纽约梅隆银行目前拥有 73,638 股该公司的股票，价值 1,336,000 美元，此前在该期间内又购买了 748 股。Charles Schwab Investment Management Inc. 在第一季度将其在 Dianthus Therapeutics 的持股增加了 0.6%。Charles Schwab Investment Management Inc. 目前拥有 168,102 股该公司的股票，价值 3,049,000 美元，此前在该期间内又购买了 1,081 股。最后，Raymond James Financial Inc. 在第二季度购买了 Dianthus Therapeutics 的新股份，价值约 27,000 美元。目前 47.53% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Dianthus Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dianthus Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.</p>
<div class="lb-trans"><p>Dianthus Therapeutics, Inc. 是一家临床阶段的生物技术公司，开发针对严重自身免疫和炎症疾病的补体治疗。该公司正在开发 DNTH103，这是一种单克隆抗体，目前处于第二阶段临床试验中，旨在治疗广泛性重症肌无力、多发性运动神经病和慢性炎症脱髓鞘多神经病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Dianthus Therapeutics</li>
<li>Business Services Stocks Investing</li>
<li>Fastenal Stock Pulls Back in October—Is It Time to Buy FAST?</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>Why Congress Is Buying Intuitive Surgical Ahead of Earnings</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>FICO’s Big Dip Could Be the Best Buying Chance of the Year</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Dianthus Therapeutics</li>
<li>商业服务股票投资</li>
<li>Fastenal 股票在十月回调——现在是购买 FAST 的时机吗？</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>为什么国会在财报前购买 Intuitive Surgical</li>
<li>三只超市股票证明它们仍然是必需品</li>
<li>FICO 的大幅下跌可能是今年最佳购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE5USA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=DNTH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Dianthus Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Dianthus Therapeutics 吗？</h2>
</div><p>Before you consider Dianthus Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dianthus Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 Dianthus Therapeutics 并不在名单上。</p>
</div><p>While Dianthus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dianthus Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dianthus Therapeutics（NASDAQ:DNTH）被 Truist Financial 的分析师给予买入评级